Interpace Biosciences Q1 2023 revenue $9.8M, up 24% YoY; turns profitable

INTERPACE BIOSCIENCES, INC.

2023-Q1 EPS reported $0.08 revenue$9,826,000

Net revenue $9.8M (+24% YoY); test volume up ~20% to record levels.
Income from continuing ops $0.4M vs loss of $1.1M; operating income $0.7M vs loss $1.0M.
Adjusted EBITDA $1.2M vs -$0.3M; cash balance $5.6M vs $2.9M a year ago.
Added 41.9M covered lives via 8 new/updated commercial contracts in Q1.
Gross profit margin improved to 61% from 59% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: revenue $9.8 million.

Period: first quarter ended March 31, 2023
Revenue: $9.8 million
Result: reported results

Exact text from the filing

today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net Revenue was $9.8 million.

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-016686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.